Gingiva-Derived dECM Hydrogels for Injectable Wound Care

Gingiva-Derived dECM Hydrogels: Why Source Tissue Matters for Injectable Wound-Care Biologics

The dominant paradigm in regenerative wound care relies on tissue-derived scaffolds — amniotic membrane, dermal matrix, placental allograft — applied as sheets or particulates to an open wound bed. A newer class of biologic, the decellularized extracellular matrix (dECM) hydrogel, reframes the question: not "what tissue can we apply to a wound" but "what regenerative instructions can we transfer to a wound bed — and can we deliver them injectably?"

A 2026 study by Liu et al. describing a gingiva-derived decellularized extracellular matrix (G-dECM) hydrogel makes the principle concrete [1]. The work, conducted in vitro, demonstrated that a hydrogel retaining the native matrix of gingival tissue — a porous, collagen-rich scaffold enriched with bioactive ECM proteins — creates a tissue-specific microenvironment promoting cell viability, osteogenic differentiation, and angiogenic marker expression. The product is investigational and not commercially available; the key insight is the principle: source tissue determines the regenerative signal, and gingiva encodes one that skin- and birth-tissue-derived matrices do not.

The dECM Concept: Why Tissue-of-Origin Determines Regenerative Signaling

Decellularized extracellular matrix is produced by culturing cells from a specific tissue, allowing them to deposit their native matrix, or by decellularizing whole tissue directly — then removing the cells while preserving the structural and signaling proteins. The result is a scaffold whose composition reflects the tissue of origin.

This is a meaningful distinction. As Nyström and colleagues outline, the extracellular matrix is not structural filler but an active signaling environment directing cell migration, proliferation, differentiation, and inflammatory resolution [9]. A 2026 review by Savitri et al. reinforces that matrix composition governs whether the wound bed resolves inflammation or becomes trapped in chronic fibrotic repair [2]. Sinha et al. (2022) demonstrated that fibroblast inflammatory priming — tissue-specific programming — determines whether the outcome is regeneration or fibrosis [11]. The implication is direct: if you want a regenerative, low-scarring signal, source your matrix from a tissue that heals regeneratively. Gingiva is such a tissue.

What Makes Gingival ECM Distinct from Amniotic Membrane

Gingival (oral mucosal) tissue has a well-documented scarless or near-scarless healing phenotype. Wong et al. (2009) demonstrated reduced scar formation in oral mucosa wounds compared to skin in both the red Duroc pig model and human subjects [6], while Mak et al. (2009) showed this is characterized by faster inflammatory resolution and tighter control of myofibroblast action [5]. Glim et al. (2013) concluded that these differences are partly encoded in ECM composition [7], and Ramalingam et al. (2023) confirmed this composition is regulated at the gene-expression level in gingival fibroblast cultures [10]. Critically, Sezgin et al. (2021) showed that oral mucosa-derived fibroblasts, applied heterotopically to cutaneous wounds, transferred a regenerative signal from their tissue of origin to a skin wound bed [8].

The distinction from amniotic membrane is structural and developmental. Amnion is optimized for fetal development and immune privilege — its growth-factor payload (EGF, bFGF, TGF-β, IL-10) evolved to support a fetus, not adult tissue repair. Gingival ECM is the matrix of an adult tissue that heals fast in a bacteria-exposed wet environment with minimal scarring. Sheets et al. (2016) confirmed in diabetic swine that matrix-derived peptides produce tissue-specific injury responses — matrix sourcing is not interchangeable across tissues [12].

The second distinguishing property is moist-environment specialization. Gingiva is evolutionarily adapted to a wet, bacteria-exposed surface — conditions found in peristomal wounds, chronic exudative ulcers, and oral cavity defects where amniotic sheet products may underperform.

Injectable Delivery vs. Sheet-Allograft Application

The form-factor difference determines which wounds the modality can reach. Sheet products require an open, accessible wound bed for fixation — irregular geometry, deep tunneled wounds, undermining pockets, and minimally invasive sites are poorly served. An injectable dECM hydrogel flows into irregular geometry, fills dead space, and can be delivered through a needle or cannula into deep pockets without open exposure. Zhang et al. (2025) fabricated granular dECM hydrogels engineered for injectable delivery and defect-space filling [4]. Wang et al. (2023) showed that an injectable dECM hydrogel promoted tissue regeneration via endogenous stem cell recruitment and suppression of fibrogenesis [3].

| Property | Amniotic Membrane Allograft | Dermal ECM Matrix | Gingiva-Derived dECM Hydrogel (Investigational) | |---|---|---|---| | Source tissue | Placenta (birth tissue) | Human/animal dermis | Gingival tissue / gingival fibroblast culture | | Regenerative signal | Fetal-development optimized | Skin-repair optimized | Scarless, moist-environment optimized | | Form factor | Sheet, patch, particulate | Sheet, meshed graft | Injectable hydrogel | | Delivery | Open-wound application + fixation | Open-wound application | Injectable via needle/cannula | | Wound geometry | Flat, accessible surfaces | Flat to moderately irregular | Irregular, deep, tunneled, pocket | | Regulatory status | FDA-regulated HCT/P; commercially available | FDA-regulated; commercially available | Preclinical / investigational only |

Candidate Indications for an Injectable Gingival dECM

No gingival-derived dECM hydrogel is FDA-approved; the indications below represent clinical reasoning from the platform science, not approved uses:

1. Irregular-geometry chronic wounds. Tunneling or undermining where a sheet graft cannot conform. 2. Peristomal wounds. Moist, bacteria-exposed, erosion-prone skin mirroring the gingival environment. The injectable format addresses defects without disrupting the appliance seal. 3. Deep pocket and sinus tract wounds. Pilonidal, perianal, or post-surgical dehiscence with tunneling where open graft application is impractical. 4. Chronic exudative wounds. Ulcers where the wet environment degrades sheet graft adherence; a matrix adapted to a wet surface may maintain signaling where sheet products are compromised.

How This Extends the Regenerative-over-Donor-Tissue Framework

The wound-care biologic market is organized around a donor-tissue paradigm: take tissue from one site (placenta, cadaveric dermis, animal pericardium), process it, and apply it elsewhere. dECM hydrogels shift toward engineered regenerative signaling — capturing the matrix instructions of a tissue with a desirable healing phenotype in a form factor matched to the target wound.

Clinical translation of dECM technology is underway in adjacent areas. A decellularized human placental ECM tissue is in clinical trials for rotator cuff repair augmentation (NCT07027735) [13]. This is complementary, not competitive: amnion remains the evidence-backed choice for flat accessible wounds; dermal matrix for structural reconstruction. Gingival dECM adds a modality for wounds defined by irregular geometry, deep spaces, and moist-environment demands that existing products serve imperfectly.

For the foundational science behind ECM scaffolding, see our amniotic membrane science guide, and for a comparison of matrix and biologic allograft options, see our dermal matrix versus biologic allograft analysis.

FAQ

No. The gingiva-derived dECM hydrogel described in the 2026 literature is an investigational, preclinical platform. No gingival dECM product is FDA-approved or commercially distributed.

Amniotic membrane is a birth-tissue allograft optimized for fetal development. Gingival dECM is engineered from the matrix of an adult tissue with a documented scarless-healing phenotype. They are complementary — amnion for flat accessible wounds, gingival dECM (if translated) for irregular, deep, or moist-environment wounds.

dECM is the structural and signaling matrix (collagen, fibronectin, laminin, proteoglycans, growth factors) deposited by cells from a specific tissue, with the cells removed. Its composition reflects the tissue of origin, which is why source-tissue selection determines the regenerative signal the matrix transmits.

References

1. Liu Y et al. Gingiva-Derived Decellularised Extracellular Matrix Hydrogel Supports Osteogenic and Angiogenic Phenotypes of 3D STRO-1(+) GMSC/HUVEC Spheroids In Vitro. International Dental Journal, 2026 Aug;76(4):109603. PMID 42066492. 2. Savitri C et al. Immunomodulatory role of decellularized extracellular matrix in skin wound healing. Materials Today Bio, 2026. PMID 41560798. 3. Wang T et al. Injectable decellularized extracellular matrix hydrogel promotes salivary gland regeneration via endogenous stem cell recruitment and suppression of fibrogenesis. Acta Biomaterialia, 2023. PMID 37557943. 4. Zhang K et al. Fabrication of granular decellularized extracellular matrix hydrogels for wound repair. Acta Biomaterialia, 2025. PMID 41038550. 5. Mak K et al. Scarless healing of oral mucosa is characterized by faster resolution of inflammation and control of myofibroblast action compared to skin wounds in the red Duroc pig model. Journal of Dermatological Science, 2009. PMID 19854029. 6. Wong JW et al. Wound healing in oral mucosa results in reduced scar formation as compared with skin: evidence from the red Duroc pig model and humans. Wound Repair and Regeneration, 2009. PMID 19769724. 7. Glim JE et al. Detrimental dermal wound healing: what can we learn from the oral mucosa? Wound Repair and Regeneration, 2013. PMID 23927738. 8. Sezgin B et al. The effects of oral mucosa-derived heterotopic fibroblasts on cutaneous wound healing. Journal of Plastic, Reconstructive & Aesthetic Surgery, 2021. PMID 33935009. 9. Nyström A et al. Matrix molecules and skin biology. Seminars in Cell & Developmental Biology, 2019. PMID 30076963. 10. Ramalingam R et al. Macromolecular crowding regulates matrix composition and gene expression in human gingival fibroblast cultures. Scientific Reports, 2023. PMID 36739306. 11. Sinha S et al. Fibroblast inflammatory priming determines regenerative versus fibrotic skin repair in reindeer. Cell, 2022. PMID 36493752. 12. Sheets AR et al. Matrix- and plasma-derived peptides promote tissue-specific injury responses and wound healing in diabetic swine. Journal of Translational Medicine, 2016. PMID 27369317. 13. Decellularized Human Placental Extracellular Matrix Tissue for Rotator Cuff Repair Augmentation. ClinicalTrials.gov, NCT07027735 (recruiting).